- Home
- CVKD vs PMN Comparison
CVKD vs PMN Comparison
Compare CVKD & PMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CVKD
- PMN
- Stock Information
- Founded
- CVKD 2022
- PMN 2004
- Country
- CVKD United States
- PMN Canada
- Employees
- CVKD N/A
- PMN N/A
- Industry
- CVKD Medicinal Chemicals and Botanical Products
- PMN Pharmaceuticals and Biotechnology
- Sector
- CVKD Health Care
- PMN Health Care
- Exchange
- CVKD Nasdaq
- PMN Nasdaq
- Market Cap
- CVKD 27.0M
- PMN 22.3M
- IPO Year
- CVKD 2023
- PMN N/A
- Fundamental
- Price
- CVKD $13.60
- PMN $0.51
- Analyst Decision
- CVKD Strong Buy
- PMN Strong Buy
- Analyst Count
- CVKD 1
- PMN 3
- Target Price
- CVKD $32.00
- PMN $4.33
- AVG Volume (30 Days)
- CVKD 28.8K
- PMN 828.7K
- Earning Date
- CVKD 11-06-2025
- PMN 11-13-2025
- Dividend Yield
- CVKD N/A
- PMN N/A
- EPS Growth
- CVKD N/A
- PMN N/A
- EPS
- CVKD N/A
- PMN N/A
- Revenue
- CVKD N/A
- PMN N/A
- Revenue This Year
- CVKD N/A
- PMN N/A
- Revenue Next Year
- CVKD N/A
- PMN N/A
- P/E Ratio
- CVKD N/A
- PMN N/A
- Revenue Growth
- CVKD N/A
- PMN N/A
- 52 Week Low
- CVKD $8.74
- PMN $0.38
- 52 Week High
- CVKD $22.90
- PMN $1.59
- Technical
- Relative Strength Index (RSI)
- CVKD 55.23
- PMN 54.11
- Support Level
- CVKD $13.40
- PMN $0.39
- Resistance Level
- CVKD $14.20
- PMN $0.61
- Average True Range (ATR)
- CVKD 0.55
- PMN 0.04
- MACD
- CVKD -0.04
- PMN 0.02
- Stochastic Oscillator
- CVKD 50.99
- PMN 57.00
About CVKD Cadrenal Therapeutics Inc.
Cadrenal Therapeutics Inc is developing tecarfarin, its drug candidate, for unmet needs in anticoagulation therapy. Tecarfarin is a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation.
About PMN ProMIS Neurosciences Inc. (ON)
ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company applies its thermodynamic, computational discovery platform, ProMIS, and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins.